Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04181827
Title A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

multiple myeloma

Therapies

Daratumumab + Dexamethasone + Pomalidomide

Bortezomib + Dexamethasone + Pomalidomide

Bortezomib + Ciltacabtagene autoleucel + Cyclophosphamide + Dexamethasone + Fludarabine + Pomalidomide

Ciltacabtagene autoleucel + Cyclophosphamide + Daratumumab + Dexamethasone + Fludarabine + Pomalidomide

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL


No variant requirements are available.